164 related articles for article (PubMed ID: 25533812)
1. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.
Safdari Y; Khalili M; Ebrahimzadeh MA; Yazdani Y; Farajnia S
Pharmacol Res; 2015 Mar; 93():1-10. PubMed ID: 25533812
[TBL] [Abstract][Full Text] [Related]
2. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
3. Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-κB signaling pathway.
Zhou M; Song X; Huang Y; Wei L; Li Z; You Q; Guo Q; Lu N
Vascul Pharmacol; 2014 Mar; 60(3):110-9. PubMed ID: 24534483
[TBL] [Abstract][Full Text] [Related]
4. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
5. Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway.
Xiao M; Men LN; Xu MG; Wang GB; Lv HT; Liu C
Eur J Pharmacol; 2014 Nov; 743():11-6. PubMed ID: 25257463
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Jian YJ; Chen CY; Jian YT; Huang YJ; Wo TY; Lin YW
Biochem Pharmacol; 2014 Mar; 88(1):119-27. PubMed ID: 24447935
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/AKT signaling pathway in obesity.
Savova MS; Mihaylova LV; Tews D; Wabitsch M; Georgiev MI
Biomed Pharmacother; 2023 Mar; 159():114244. PubMed ID: 36638594
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham J
Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
10. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
[TBL] [Abstract][Full Text] [Related]
12. Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Zhong Z; Tan W; Chen X; Wang Y
Eur J Pharmacol; 2014 Aug; 737():1-10. PubMed ID: 24824922
[TBL] [Abstract][Full Text] [Related]
13. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.
Cui W; Zhang S; Shan C; Zhou L; Zhou Z
FEBS J; 2013 Aug; 280(16):3962-74. PubMed ID: 23786162
[TBL] [Abstract][Full Text] [Related]
14. Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy.
Sylvester PW; Ayoub NM
Anticancer Agents Med Chem; 2013 Sep; 13(7):1039-47. PubMed ID: 23272909
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
16. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
Chen YL; Law PY; Loh HH
Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
Dong Y; Li A; Wang J; Weber JD; Michel LS
Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway.
Shao N; Lu Z; Zhang Y; Wang M; Li W; Hu Z; Wang S; Lin Y
Cancer Lett; 2015 Aug; 364(2):165-72. PubMed ID: 25979232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
